Celgene buys part of Boston cancer drug firm

After paying $100 million in 2013 for the option to buy Boston-based Acetylon Pharmaceuticals and then passing on a deal this August, Celgene purchased part of the cancer drug developer on Friday for an undisclosed sum.Privately-held Acetylon, which has 40 employees, said that it had been acquired by Celgene (Nasdaq: CELG). But first, the company will spin out a new firm to develop some of its novel drug candidates. The new entity, Regenacy Pharmaceuticals, will be operated out of Acetylon&rsquo